This company listing is no longer active
Resumen de acción VIFN
Vifor Pharma AG, a pharmaceutical company, focuses on the development, manufacture, and commercialization of pharmaceutical products in Switzerland, rest of Europe, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Competidores de Vifor Pharma AG
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | CHF166.15 |
| 52 Week High | CHF197.20 |
| 52 Week Low | CHF157.75 |
| Beta | 1.04 |
| 1 Month Change | -1.37% |
| 3 Month Change | -5.33% |
| 1 Year Change | 1.93% |
| 3 Year Change | -7.67% |
| 5 Year Change | 33.03% |
| Change since IPO | 1,057.84% |
Noticias y actualizaciones recientes
Recent updates
I Ran A Stock Scan For Earnings Growth And Vifor Pharma (VTX:VIFN) Passed With Ease
Dec 14
Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?
Nov 24Here's Why We Think Vifor Pharma (VTX:VIFN) Is Well Worth Watching
Sep 03Is Vifor Pharma (VTX:VIFN) A Risky Investment?
Aug 17Do Investors Have Good Reason To Be Wary Of Vifor Pharma AG's (VTX:VIFN) 1.6% Dividend Yield?
May 10Vifor Pharma (VTX:VIFN) Seems To Use Debt Quite Sensibly
Mar 30Could The Vifor Pharma AG (VTX:VIFN) Ownership Structure Tell Us Something Useful?
Mar 10How Much Did Vifor Pharma's(VTX:VIFN) Shareholders Earn From Share Price Movements Over The Last Year?
Feb 19Key Things To Consider Before Buying Vifor Pharma AG (VTX:VIFN) For Its Dividend
Jan 15
Vifor Pharma AG's (VTX:VIFN) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Dec 24Is Vifor Pharma (VTX:VIFN) Using Too Much Debt?
Dec 01Getting In Cheap On Vifor Pharma AG (VTX:VIFN) Might Be Difficult
Jul 17Rentabilidad de los accionistas
| VIFN | CH Pharmaceuticals | Mercado CH | |
|---|---|---|---|
| 7D | 0.4% | -0.2% | -0.7% |
| 1Y | 1.9% | 9.7% | -4.9% |
Rentabilidad vs. Industria: VIFN exceeded the Swiss Pharmaceuticals industry which returned -0.8% over the past year.
Rentabilidad vs. Mercado: VIFN exceeded the Swiss Market which returned -19% over the past year.
Volatilidad de los precios
| VIFN volatility | |
|---|---|
| VIFN Average Weekly Movement | 2.3% |
| Pharmaceuticals Industry Average Movement | 3.1% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 2.0% |
Precio estable de las acciones: VIFN has not had significant price volatility in the past 3 months.
Volatilidad a lo largo del tiempo: VIFN's weekly volatility (2%) has been stable over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1872 | 2,200 | n/a | www.viforpharma.com |
Resumen de fundamentos de Vifor Pharma AG
| Estadísticas fundamentales de VIFN | |
|---|---|
| Capitalización bursátil | CHF10.78b |
| Beneficios(TTM) | CHF146.60m |
| Ingresos (TTM) | CHF1.81b |
73.5x
Ratio precio-beneficio (PE)5.9x
Ratio precio-ventas (PS)¿Está VIFN sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de VIFN | |
|---|---|
| Ingresos | CHF1.81b |
| Coste de los ingresos | CHF671.80m |
| Beneficio bruto | CHF1.14b |
| Otros gastos | CHF993.70m |
| Beneficios | CHF146.60m |
Últimos beneficios comunicados
Dec 31, 2021
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 2.26 |
| Margen bruto | 62.93% |
| Margen de beneficio neto | 8.09% |
| Ratio deuda/patrimonio | 13.6% |
¿Cómo se ha desempeñado VIFN a largo plazo?
Ver rendimiento histórico y comparativa